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Editorial

LKB1 in transmembrane receptor signaling
Imoh S. Okon and Ming-Hui Zou
Signal processing and integration is critical in
physiology, as it is in disease conditions. Conversion of
extracellular signals into appropriate biological responses
by cell membrane receptors, and subsequent extinction
of signaling events is critical to cellular hemostasis.
Defective trafficking, internalization or degrardation of
transmembrane receptors (TMRs) result in perturbed
activation of signaling networks, which play essential
roles in disease initiation or accentuation. In our recent
study, we found that liver kinase B1 (LKB1), a calciumcalmodulin family member abrogated neuropilin-1 (NRP1) protein in lung cancer clinical specimens and cell lines
[1]. Surprisingly, this observation was reminiscent to our
previous finding in which LKB1 attenuated the activation
of a repertoire of receptor tyrosine kinases (RTKs),
including EGFR, ErbB2, HGFR (c-Met) and EphA2
[2]. The regulation of TMRs by LKB1 appears to be a
recurring pattern in cancer cells but occur via different
mechanisms. Unlike LKB1-mediated dephosphorylation
of RTKs via accentuation of selected phosphatase activity,
NRP-1 attenuation was promoted by LKB1-RAB7
GTPase complex [1, 2]. We demonstrated for the first
time that LKB1 is a RAB7 effector and suppresses tumor
angiogenesis by promoting cellular trafficking of NRP1 from RAB7 vesicles to the lysosome for degradation.
LKB1 specifically bound active GTP-Q67L RAB7
construct, but not the dominant-negative GDP-T22N
form. NRP-1 localization within RAB7, a late endocytic
target was not detected in early (RAB5) or recycling
(RAB11) endosomal markers [1]. With over 60 different
mammalian RAB family-members, the selectivity may be
context-dependent, and the relationship between LKB1
and RAB family-members requires further investigation.
Our findings indicated that hypoxia, a property of tumor
micro-environment promotes LKB1 nuclear export to
the cytosol, where it interacts with NRP-1 and RAB7
[1]. LKB1 expression was consistent with its tumor
suppression functions, which included inhibition of
angiogenesis and tumor growth in vivo. Conversely, loss
of LKB1 exacerbated tumor-enhancing phenotypes [1].
We have recently observed a similar inverse expression
profile between LKB1 and NRP-1 proteins within
endometrial cancer specimens. We found that NRP1 positively correlated with NEDD9 pro-metastatic
protein. As expected, LKB1 abrogation of NRP-1 protein
correlated with decreased metastatic potential of cancer
cells in vitro (unpublished observations).
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In contrast to well-established RTKs, such as
EGFR that have been studied for decades, several NRP1 functions remain relatively unknown. NRP-1 is a nontyrosine kinase, type-I transmembrane receptor that
is largely associated with the VEGF receptor family.
Canonical NRP-1 functions in tumor angiogenesis is
strongly linked to VEGFR2. In our studies, NRP-1mediated tumor phenotypes were independent of VEGFR2
in lung and endometrial cancer specimens [1]. Angiogenicswitch which is characterized by heightened development
of new blood vessels, serve to enhance nutrition and
oxygen availability required for tumor progression,
and NRP-1 may be critical to the process. LKB1, as a
key regulator of TMRs influences receptor activation,
trafficking, internalization, recycling and degradation.
As expected, the attenuation of TMR-mediated signaling
events impact biological and functional outcomes, such
as tumor angiogenesis and migration. We have found
decreased recycling potential in LKB1-positive cells
relative to controls (LacZ) following ligand stimulation
at different time intervals. We also observed that LKB1
associates with another GTPase protein, dynamin2
(unpublished observations), suggesting that LKB1 may
possess TMR trafficking functions via selective complex
formation with GTPase family members.
LKB1-mediated targeting of TMRs appear to
be specific and highly selective. For example, NRP-2,
an isoform of neuropilin receptors was unaffected by
LKB1. Unlike NRP-1, NRP-2 protein was stable under
varying conditions, including hypoxia. This observation
is consistent with a recent report that described NRP1 attenuation under starvation compared with robust
NRP-2 expression [3]. The reasons for these differences
are unclear, however both receptors share only a 44%
sequence homology which may account for differential
regulation with respect to LKB1. These differences may
also explain divergent functions in development and
disease. Although both are important in the vascular
system, NRP-1 is widely linked with tumor angiogenesis
while NRP-2 is associated with lymphangiogenesis
[4]. Interestingly, LKB1 failed to abrogate TMRs at the
message level, suggesting posttranslational modifications
which may include, acetylation, phosphorylation or
farnesylation. LKB1 possesses a farnesylation site
at the C-terminal domain, and potential functions of
the domain remains to be explored. At the last count,
LKB1 modulatory functions involved approximately
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13 downstream substrates, including the well-described
energy sensor, AMP-activated protein kinase (AMPK).
Such orchestrated regulation by LKB1 may directly
modulate several signaling networks or occur indirectly
via these substrates. Although several roles have been
ascribed to LKB1 in the last decade, ranging from
hematopoietic stem cell survival, tumor suppressor and
cardiovascular functions [1, 5-7], it appears that the
ubiquitously expressed LKB1 gene has yet to play more
critical roles in disease and physiology.
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